← Leaderboards
Vijaya Ramesh
Massachusetts General Hospital
$9,458,883
Attributed
$12,558,182
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$12,558,182 · 14
By mechanism
R01$8,069,817 · 4
P01$1,229,692 · 3
R21$909,015 · 2
P30$899,524 · 1
R61$840,000 · 1
R33$420,000 · 1
Top collaborators
- Stephen J Haggarty5 shared
- Scott R Plotkin4 shared
- Xandra Owens Breakefield3 shared
- Casey A Maguire3 shared
- Marianne James2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- William F Pirl$2,647,744
- Jennifer Temel$9,010,566
- Jamie S Ostroff$23,039,922
- David A Boas$41,142,921
- Pradeep G Bhide$8,542,290
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsSignal TransductionMutationClinical TrialsPathway InteractionsFrap1 GeneAllelesPharmaceutical PreparationsSirolimusUnited States National Institutes Of HealthResponseGenome EditingNull LymphocytesCell LineLaboratory MouseMorbidity - Disease RateBrainTuberous SclerosisCci-779Pre-ClinicalBaseCollaborationsMtor InhibitorDrug Combinations
Grant awards (43)
NF2-Associated Meningiomas: From Omics Discovery to Targeted Therapy$613,836
R01 · FY2024 · NS · contact PI
NF2-Associated Meningiomas: From Omics Discovery to Targeted Therapy$632,818
R01 · FY2023 · NS · contact PI
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2023 · NS · contact PI
NF2-associated meningiomas: From omics discovery to targeted therapy$632,818
R01 · FY2022 · NS · contact PI
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2022 · NS · contact PI
Gene therapy for Tuberous Sclerosis$420,000
R33 · FY2022 · NS
NF2-associated meningiomas: From omics discovery to targeted therapy$632,818
R01 · FY2021 · NS · contact PI
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2021 · NS · contact PI
NF2-associated meningiomas: From omics discovery to targeted therapy$649,818
R01 · FY2020 · NS · contact PI
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2020 · NS · contact PI
Gene therapy for tuberous sclerosis$420,000
R61 · FY2020 · NS
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$503,851
R01 · FY2019 · NS · contact PI
Gene therapy for tuberous sclerosis$420,000
R61 · FY2019 · NS
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$389,008
R01 · FY2019 · CA · contact PI
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$401,040
R01 · FY2018 · CA · contact PI
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$401,017
R01 · FY2017 · CA · contact PI
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma$400,389
R01 · FY2016 · CA · contact PI
Preclinical Treatment for NF2-Associated Tumors$258,390
R21 · FY2014 · NS · contact PI
Preclinical Treatment for NF2-Associated Tumors$217,500
R21 · FY2013 · NS · contact PI
Genes that deregulate mTOR signaling as candidates for autism spectrum disorders$196,875
R21 · FY2008 · MH · contact PI
Cell Biology and Immunology$159,634
P50 · FY2008 · NS · contact PI
Genes that deregulate mTOR signaling as candidates for autism spectrum disorders$236,250
R21 · FY2007 · MH · contact PI
Core--Monoclonal antibody production$201,875
P30 · FY2007 · NS · contact PI
Cell Biology and Immunology$191,627
P01 · FY2007 · NS · contact PI
Core--Monoclonal antibody production$188,055
P30 · FY2006 · NS · contact PI
Cell Biology and Immunology$183,752
P01 · FY2006 · NS · contact PI
2006 NF Consortium for NF1, NF2 and Schwannomatosis$30,500
R13 · FY2006 · NS · contact PI
Cell Biology and Immunology$183,752
P01 · FY2005 · NS
Core--Monoclonal antibody production$177,442
P30 · FY2005 · NS
CHARACTERIZATION OF TSC PROTEIN HAMARTIN AND TUBERIN$173,000
R01 · FY2005 · NS
Cell Biology and Immunology$183,052
P01 · FY2004 · NS
CHARACTERIZATION OF TSC PROTEIN HAMARTIN AND TUBERIN$173,000
R01 · FY2004 · NS
Core--Monoclonal antibody production$168,491
P30 · FY2004 · NS
CHARACTERIZATION OF TSC PROTEIN HAMARTIN AND TUBERIN$173,000
R01 · FY2003 · NS
Core--Monoclonal antibody production$163,661
P30 · FY2003 · NS
CHARACTERIZATION OF TSC PROTEIN HAMARTIN AND TUBERIN$173,000
R01 · FY2002 · NS
CORE--CELL BIOLOGY AND IMMUNOLOGY$69,267
P01 · FY2002 · NS
CHARACTERIZATION OF TSC PROTEINS HAMARTIN AND TUBERIN$0
P01 · FY2002 · NS
CHARACTERIZATION OF TSC PROTEIN HAMARTIN AND TUBERIN$173,000
R01 · FY2001 · NS
MOLECULAR GENETICS OF TUBEROUS SCLEROSIS 2$148,221
P01 · FY2001 · NS
CORE--CELL BIOLOGY AND IMMUNOLOGY$69,267
P01 · FY2001 · NS
CHARACTERIZATION OF TSC PROTEINS HAMARTIN AND TUBERIN$0
P01 · FY2001 · NS
CORE--CELL BIOLOGY AND IMMUNOLOGY$200,754
P01 · FY2000 · NS